The investigational Nutlin family antagonist idasanutlin demonstrated significant activity and was well tolerated after multiple cycles of exposure in patients with refractory polycythemia vera (PV).

Data from a 2-part single-institution, open-label, dose-escalation phase I study showed a 75% overall response rate when idasanutlin was given as a monotherapy or in combination with pegylated interferon, said John Mascarenhas, MD, at the 2017 ASH Annual Meeting.  Click the link below for the full story:

[contentcards url=”http://www.targetedonc.com/conference/2017-ash-mpn/nutlin-antagonist-shows-activity-in-polycythemia-vera” target=”_blank”]